12 July 2016 - PHARMAC is seeking feedback on a proposal for a sole supply arrangement for Mylan New Zealand Limited’s (Mylan) brand of metoprolol tartrate injection 1 mg per ml, 5 ml vial (Metoprolol IV Mylan) as a result of a provisional agreement with Mylan.

In summary, this proposal would result in:

• Metoprolol IV Mylan being funded in the community and DHB hospitals from a date to be determined. Listing in the cardiovascular system group in the Pharmaceutical Schedule would occur subject to Medsafe approval of the pharmaceutical
• Metoprolol IV Mylan being the only subsidised brand of metoprolol tartrate inj 1 mg per ml, 5 ml vial in the community (Sole Supply Status) and DHB hospitals (Hospital Supply Status) for a period of three years following a transition period to be determined by PHARMAC.
• The Lopresor brand of metoprolol tartrate injection 1 mg per ml, 5 ml vial being delisted from the Pharmaceutical Schedule when Sole Supply Status and Hospital Supply Status of the Mylan brand is implemented.

View PHARMAC Consultation